Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

60.0%

3 terminated/withdrawn out of 5 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

100%

5 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
5(100.0%)
5Total
Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00088166Phase 3Completed

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Role: collaborator

NCT00226655Phase 3Completed

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Role: collaborator

NCT00300196Phase 3Terminated

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Role: lead

NCT00141011Phase 3Terminated

Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Role: lead

NCT00226668Phase 3Withdrawn

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

Role: collaborator

All 5 trials loaded